Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma

NCT00385853 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00385853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00385853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2006
Completion date
September 30, 2011
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma